Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured
islets. Patients will receive three times a week AAT infusions in the peri-transplant period
for three weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) University of Iowa
Treatments:
Alpha 1-Antitrypsin Antilymphocyte Serum Basiliximab Etanercept Protein C Inhibitor Thymoglobulin